Teva secures worldwide rights to investigational at‑home agitation treatment BXCL501
Teva Pharmaceutical Industries announced that it has completed the purchase of the global rights to BXCL501, a dexmedetomidine sublingual film currently under FDA review for home use in acute agitation linked to schizophrenia or bipolar disorder. The transaction, carried out through a court‑supervised Section 363 sale of BioXcel Therapeutics’ neuroscience assets, provides Teva with a late‑stage candidate and the already‑approved film IGALMI®. The deal includes an upfront payment of $57.5 million and up to $67.5 million in milestone‑based contingent payments.
Why it matters
The acquisition adds a potential first‑in‑class at‑home therapy to Teva’s neuroscience portfolio, which could open a new revenue stream if the FDA grants approval. The company says the asset aligns with its Pivot to Growth strategy and supports its shift toward innovative medicines.
Key facts
- 1Teva bought worldwide rights to BXCL501 and the approved film IGALMI® from BioXcel Therapeutics' assets. globenewswire.com
- 2The purchase was executed via a Section 363 bankruptcy sale approved by the U.S. Bankruptcy Court. globenewswire.com
- 3The transaction closed on October 27 2026. globenewswire.com
- 4Teva paid $57.5 million upfront and may pay up to $67.5 million in additional, time‑based and sales‑milestone payments. globenewswire.com
- 5BXCL501 is under FDA review as a sublingual film for at‑home treatment of acute agitation in adults with schizophrenia or bipolar I or II disorder. stocktitan.net
- 6Acute agitation affects between 25 % and 40 % of patients with these conditions. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.